TBIO telesisbio.com: Rentabilitas operasi

Telesis Bio Inc. (TBIO) - logo korporat

Telesis Bio, Inc. (TBIO) is making a breakthrough in synthetic biology by offering the BioXp system for rapid gene synthesis. The operating profit margin confirms this potential, and this metric equals -200.80. Growth relies on the automation of R&D processes within the pharmaceutical sector, although risks are linked to the need to scale B2B trust in the accuracy of robotic solutions within a professional environment.

TBIO: Margin dodolan operasi Telesis Bio Inc. 28.04.2023 - 05.10.2024

Rincian metrik keuangan lan pasar Telesis Bio, Inc. (TBIO)

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
Ringkesan analisis perusahaan:Telesis Bio, Inc, TBIO
Produk merek Telesis Bio, Inc

The resilience of Telesis Bio, Inc. (TBIO) is determined by its ability to monetize its leadership in DNA and mRNA synthesis automation amid large-scale R&D expenditures. By analyzing the operating profit spread, an investor can identify the portion of revenue remaining after all production costs are paid, but before accounting for financial obligations and taxes, which allows for an objective assessment of the business model's internal efficiency and the determination of the company's fair market discount.

Analisis pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Sangamo Therapeutics Inc. - Margin operasi|NAUT - Margin operasi|MGX: Margin operasi|Margin dodolan operasi Precision BioSciences, Inc.|GBIO (Generation Bio) - Margin operasi|Boundless Bio Inc. (BOLD) - Rentabilitas kegiatan operasi|Margin dodolan operasi XCUR (exicuretx.com)|Imunon Inc - Rentabilitas dodolan miturut bathi operasi|Margin operasi PHIO (Phio Pharmaceuticals Corp)|Tingkat bathi operasi MBIO|RNAZ - Rentabilitas operasi|Tingkat bathi operasi BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Rentabilitas operasi|Bluebird Bio - Tingkat bathi operasi|IPA (ImmunoPrecise Antibodies Ltd) - Margin operasi|Rentabilitas dodolan operasi Omega Therapeutics, Inc. OMGA|Margin operasi OMIC|RGLS (Regulus Therapeutics Inc.) - Tingkat bathi operasi|Margin operasi SYRS (Syros Pharmaceuticals Inc.)|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi